- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03379025
Effects of Electronic Cigarettes in Cigarette Smokers With Mild to Moderate COPD
Effects of Electronic Cigarettes on Smokers With Mild to Moderate Chronic Obstructive Pulmonary Disease
Study Overview
Detailed Description
Electronic cigarettes are devices that heat a solution containing nicotine to form an aerosol that is then inhaled by the user. Electronic cigarettes are used by many smokers, including smokers with chronic health conditions such as COPD. Given that e-cigarettes are still relatively new, their effects on health are not well defined.
It is important to understand how electronic cigarettes affects symptoms and lung function in smokers with COPD to determine the short-term safety of these products. To do this, an initial step involves observing the extent to which smokers substitute their conventional cigarette use with electronic cigarette use and change their exposure to tobacco use biomarkers.
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 10 pack year smoking history
- Daily use of at least 5 cigarettes
- No plan to quit cigarettes in the next 30 days
- Willing to use e-cigarettes
- Diagnosis of COPD (FEV1/forced vital capacity [FVC] <0.70) with mild (FEV1 >80% predicted) or moderate (FEV1 <80% but >50% predicted) airflow limitation (post-bronchodilator); confirmed by spirometry
- English-speaking
Exclusion Criteria:
- Past 30-day use of nicotine-containing products (cigars, cigarillos, hookah, electronic cigarettes, smokeless tobacco, nicotine replacement therapy)
- Past 30 day use of inhaled drugs (marijuana, crack)
- Pregnant or breastfeeding
- Planning to become pregnant within the next 3 months or unable to agree to use appropriate contraception during study
- Pulmonary disease other than COPD or asthma
- Ever requiring mechanical ventilation
- 2 or more hospitalizations for COPD in the past 12 months
- Cardiac hospitalization in the past 6 months
- Active chest pain or palpitations
- Uncontrolled hypertension (blood pressure >160/100)
- Oxygen therapy
- Inability or contraindication to perform spirometry (e.g. recent eye, thoracic, or abdominal surgery)
- Known allergy to propylene glycol or vegetable glycerin
- Unable to consent or complete assessments
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Early Intervention Group
JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
|
electronic cigarette and cartridge refills (also known as pods)
Other Names:
|
OTHER: Delayed Intervention Group
After a 12 week period of no electronic cigarette use, JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
|
electronic cigarette and cartridge refills (also known as pods)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cigarettes per day
Time Frame: baseline and 12 weeks
|
Change in self-reported cigarettes per day from Week 0 to Week 12
|
baseline and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in urine anabasine
Time Frame: baseline and 12 weeks
|
Change in tobacco biomarker anabasine from Week 0 to Week 12
|
baseline and 12 weeks
|
Change in urine cotinine
Time Frame: baseline and 12 weeks
|
Change in nicotine metabolite cotinine from Week 0 to Week 12
|
baseline and 12 weeks
|
Change in exhaled carbon monoxide
Time Frame: baseline and 12 weeks
|
Change in exhaled carbon monoxide from Week 0 to Week 12
|
baseline and 12 weeks
|
Change in pulmonary function
Time Frame: baseline and 12 weeks
|
Change in post-bronchodilator forced expiratory volume in one second (FEV1) from Week 0 to Week 12
|
baseline and 12 weeks
|
Transition Dyspnea Index
Time Frame: baseline and 12 weeks
|
Change in Transition Dyspnea Index at Week 12 from the Baseline Dyspnea Index at Week 0
|
baseline and 12 weeks
|
St. George's Respiratory Questionnaire
Time Frame: baseline and 12 weeks
|
Change in quality of life as measured by the St. George's Respiratory Questionnaire from Week 0 to Week 12
|
baseline and 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sustained change in cigarettes per day
Time Frame: 12 weeks and 24 weeks for immediate intervention group; 24 weeks and 36 weeks for delayed intervention group
|
Assess whether any changes in cigarettes per day after 12 weeks of receiving e-cigarettes are sustained after an additional 12 weeks
|
12 weeks and 24 weeks for immediate intervention group; 24 weeks and 36 weeks for delayed intervention group
|
Sustained change in urine anabasine
Time Frame: 12 weeks and 24 weeks for immediate intervention group; 24 weeks and 36 weeks for delayed intervention group
|
Assess whether any changes in urine anabasine after 12 weeks of receiving e-cigarettes are sustained after an additional 12 weeks
|
12 weeks and 24 weeks for immediate intervention group; 24 weeks and 36 weeks for delayed intervention group
|
Sustained change in urine cotinine
Time Frame: 12 weeks and 24 weeks for immediate intervention group; 24 weeks and 36 weeks for delayed intervention group
|
Assess whether any changes in urine cotinine after 12 weeks of receiving e-cigarettes are sustained after an additional 12 weeks
|
12 weeks and 24 weeks for immediate intervention group; 24 weeks and 36 weeks for delayed intervention group
|
Sustained change in exhaled carbon monoxide
Time Frame: 12 weeks and 24 weeks for immediate intervention group; 24 weeks and 36 weeks for delayed intervention group
|
Assess whether any changes in exhaled carbon monoxide after 12 weeks of receiving e-cigarettes are sustained after an additional 12 weeks
|
12 weeks and 24 weeks for immediate intervention group; 24 weeks and 36 weeks for delayed intervention group
|
Sustained change in pulmonary function
Time Frame: 12 weeks and 24 weeks for immediate intervention group; 24 weeks and 36 weeks for delayed intervention group
|
Assess whether any changes in post-bronchodilator FEV1 after 12 weeks of receiving e-cigarettes are sustained after an additional 12 weeks
|
12 weeks and 24 weeks for immediate intervention group; 24 weeks and 36 weeks for delayed intervention group
|
Sustained change in transition dyspnea index
Time Frame: 12 weeks and 24 weeks for immediate intervention group; 24 weeks and 36 weeks for delayed intervention group
|
Assess whether any changes in post-bronchodilator FEV1 after 12 weeks of receiving e-cigarettes are sustained after an additional 12 weeks
|
12 weeks and 24 weeks for immediate intervention group; 24 weeks and 36 weeks for delayed intervention group
|
Sustained change in St. George's Respiratory Questionnaire
Time Frame: 12 weeks and 24 weeks for immediate intervention group; 24 weeks and 36 weeks for delayed intervention group
|
Assess whether any changes in quality of life as measured by the St. George's Respiratory Questionnaire after 12 weeks of receiving e-cigarettes are sustained after an additional 12 weeks
|
12 weeks and 24 weeks for immediate intervention group; 24 weeks and 36 weeks for delayed intervention group
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2017P002418
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use
-
University of VirginiaVirginia Foundation for Healthy YouthRecruitingTobacco Use | Electronic Cigarette Use | Tobacco Use CessationUnited States
-
Vanderbilt University Medical CenterCompletedTobacco Use | Tobacco Use Cessation
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco DependenceUnited States
-
British American Tobacco (Investments) LimitedCompletedTobacco Use | Tobacco SmokingUnited States
-
Philip Morris Products S.A.CompletedSmoking | Tobacco Use | Tobacco SmokingUnited Kingdom
Clinical Trials on Electronic cigarette
-
Virginia Commonwealth UniversityCompletedElectronic CigarettesUnited States
-
University of California, San FranciscoNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsRecruitingCardiovascular Risk Factor | Nicotine DependenceUnited States
-
University of California, San FranciscoNational Cancer Institute (NCI); National Institutes of Health (NIH); Food and...CompletedCardiovascular Risk Factor | Nicotine DependenceUnited States
-
Karolinska InstitutetCompleted
-
GWT-TUD GmbHTerminated
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedEndothelial Dysfunction | Biochemical MarkersUnited States
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); Roswell Park Cancer InstituteCompleted
-
Queen's University, BelfastUnknownAcute Lung InjuryUnited Kingdom
-
University of AthensUnknown
-
Miami VA Healthcare SystemUnknownSmoking Cessation | Airway Morbidity | Smoking, Tobacco | Smoking, Cigarette | Nicotine Adverse ReactionUnited States